Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1988 1
1994 1
2003 1
2004 3
2005 6
2006 5
2007 3
2008 2
2009 2
2010 3
2011 4
2012 2
2013 3
2014 6
2015 9
2016 6
2017 7
2018 12
2019 12
2020 6
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 32366637

90 results
Results by year
Filters applied: . Clear all
Page 1
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Morgan JR, et al. J Subst Abuse Treat. 2018 Feb;85:90-96. doi: 10.1016/j.jsat.2017.07.001. Epub 2017 Jul 3. J Subst Abuse Treat. 2018. PMID: 28733097 Free PMC article.
Implementation challenges for long-acting antivirals as treatment.
Havlir D, Gandhi M. Havlir D, et al. Curr Opin HIV AIDS. 2015 Jul;10(4):282-9. doi: 10.1097/COH.0000000000000158. Curr Opin HIV AIDS. 2015. PMID: 26049955 Free PMC article. Review.
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, Levin FR, Dakwar E, Mariani JJ, Nunes EV. Sullivan M, et al. Am J Psychiatry. 2017 May 1;174(5):459-467. doi: 10.1176/appi.ajp.2016.16050548. Epub 2017 Jan 10. Am J Psychiatry. 2017. PMID: 28068780 Free PMC article. Clinical Trial.
Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.
Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF. Laffont CM, et al. J Clin Pharmacol. 2016 Jul;56(7):806-15. doi: 10.1002/jcph.665. Epub 2016 Mar 11. J Clin Pharmacol. 2016. PMID: 26479717 Clinical Trial.
A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence.
Nasser AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK. Nasser AF, et al. Clin Pharmacokinet. 2014 Sep;53(9):813-24. doi: 10.1007/s40262-014-0155-0. Clin Pharmacokinet. 2014. PMID: 25015174 Clinical Trial.
90 results
Jump to page